In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan. In May 2017, Conatus announced that Novartis had exercised its license option following initiation of the Phase 2b ENCORE-LF clinical trial.
Emricasan is a first-in-class, orally active pancaspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. We believe that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease.
Conatus announced its first internally developed product candidate, CTS-2090, in March 2019.